enGene Therapeutics Warrants
ENGNW
24 hedge funds and large institutions have $6.26M invested in enGene Therapeutics Warrants in 2023 Q4 according to their latest regulatory filings, with 24 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$727K |
| 2 |
BOCH
Blue Owl Capital Holdings
New York
|
+$365K |
| 3 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
+$365K |
| 4 |
Calamos Advisors
Naperville,
Illinois
|
+$192K |
| 5 |
SCM
Saba Capital Management
New York
|
+$177K |
Top Sellers
ENGNW Hedge Fund Activity: Q4 2023 in Review
24 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in enGene Therapeutics Warrants (ENGNW) for Q4 2023, worth a combined $6.26M.
Buyers outnumbered sellers: 24 funds opened new ENGNW positions and 0 closed out — a net gain of 24 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was BVF Inc, opening a new position worth an estimated $727K.
- 24 institutional investors held enGene Therapeutics Warrants (ENGNW) as of Q4 2023, up from 0 in Q3 2023.
- Funds reported $6.26M of enGene Therapeutics Warrants stock for Q4 2023.
- 24 funds opened new enGene Therapeutics Warrants positions in Q4 2023 and 0 closed out, a net change of +24 holders.
- The largest enGene Therapeutics Warrants buyer in Q4 2023 was BVF Inc, an estimated $727K added.
Based on aggregated 13F filings for Q4 2023.